ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer ...
Single agent lorigerlimab demonstrated encouraging preliminary clinical activity in clear cell gynecologic cancer (CCGC) with a confirmed ORR of ...
BioInvent reported updated Phase 1/2 data from Part B of its ongoing study of BI-1808 combined with pembrolizumab in heavily pretreated, platinum-resistant recurrent ovarian cancer, showing a 24% ...
Amplia Therapeutics has advanced its cancer drug narmafotinib across four trials, with data suggesting it may work ...
HRDPath, an AI model, analyzes tissue images to identify ovarian cancers with homologous recombination deficiency.
The investigational folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC) sofetabart mipitecan (LY4170156) ...
An AI model created by researchers at King's can detect signs of faulty repair mechanisms in ovarian cancer cells, potentially leading to a low-cost ...
A retrospective single-center cohort of 128 patients associated frontline bevacizumab with longer overall survival in ...
Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase ...
Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in ...
Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian Cancer ...
The Telegraph spoke to three grieving Australian families who say enough is enough, backing our campaign with the Ovarian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results